Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Montalescot, G.
Right arrow Articles by Collet, J.P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Montalescot, G.
Right arrow Articles by Collet, J.P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Glycoprotein IIb/IIIa receptors and primary stenting in acute myocardial infarction

G. Montalescot1, R. Choussat and J.P. Collet

Centre Hôpital Universitaire, Pitié-Salpétriére, Paris, France

1 Correspondence: Professor Gilles Montalescot, MD, PhD, Department of Cardiology, Universitaire Pitié-Salpétrière, 47 Boulevard del l'Hôpital, Paris, France 75651.

Abstract

The past 15 years have seen great progress in the treatment of acute myocardial infarction (MI), with the development of thrombolytic agents and catheter-based reperfusion strategies such as percutaneous transluminal coronary angioplasty (PTCA). Because both thrombolytics and PTCA have limitations in achieving large-vessel patency, stenting has been adopted as the treatment modality of choice for planned elective revascularization. In addition, an increasing number of studies have indicated that the class of antiplatelet drugs known as glycoprotein (GP) IIb/IIIa receptor inhibitors can reduce ischaemic events following both elective and acute percutaneous coronary interventions. The results have been unequivocally positive regarding the benefits of these agents in PTCA procedures, but less information is available on their use with primary stenting in acute MI. This article reviews the rationale and emerging evidence supporting the use of GP IIb/IIIa receptor inhibitors in conjunction with primary stenting for acute MI.

Key Words: GP IIb/IIIa receptor inhibitor • primary stenting • acute myocardial infarction • percutaneous transluminal coronary angioplasty • fibrinolysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.